1 December 2022
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G et al, on behalf of the BIG 3–07/TROG 07.01 trial investigators.
Lancet 2022; 400: 431-440.
This multicentre study included 1608 patients in a two by two design. The five-year freedom from recurrence rate was higher after booster radiotherapy (97.1 versus 92.7 per cent, P<0.001), but with higher rates of breast pain and induration.
Comment: Booster radiotherapy improved local control, and women can be warned concerning the after effects.
18 October 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.